Mingqi XIE, Ph.D.

School of Life Sciences

Laboratory for Biosystems Engineering

CONTACT

Email: xiemingqi@westlake.edu.cn

Website:

Mingqi XIE, Ph.D.

School of Life Sciences

Laboratory for Biosystems Engineering

CONTACT

Email: xiemingqi@westlake.edu.cn

Website:

“Grateful for this once-in-a-lifetime opportunity to simultaneously witness, create and influence history at Westlake University.”

Biography

Growing up  among three different cultures and having lived in Germany, France and China  until Highschool graduation, Mingqi completed his entire higher education at the  Swiss Federal Institute of Technology in Zurich and Basel (ETH Zurich,  Switzerland). In 2017, Mingqi received his doctoral degree in biotechnology and  bioengineering under the guidance of Prof. Dr. Martin Fussenegger. His research  focuses on the design of novel medically-relevant cell functions using synthetic  biology-inspired engineering principles. After spending another two years as a  research associate and eventually contributing to a total of 16 academic  publications at the ETH Zurich, Mingqi joined Westlake University in August 2019  as an assistant professor (independent PI), where he currently leads the  Laboratory of Biosystems Engineering in the School of Life Sciences.

 

Research

Research in  Xie’s lab is committed to the tailor-design of improved therapeutic strategies  for diagnosis and treatment of complicated diseases using principles of cell  engineering and personalized medicine. Interdisciplinary collaborations with  various academic and clinical fields, such as material sciences, protein design  or basic medical research, are strongly fostered. Current research directions  include:

1) Development  and characterization of novel molecular tools for cell engineering

2) Engineering  of clinically applicable primary cells for cell-based therapies

3) Creation of  gene circuits-based solutions for high-precision targeting of cancer   

4) Establishment  of high-throughput and resource-efficient drug discovery strategies to identify  bioactive natural compounds

 

Disciplines: Molecular  Biology (Cell Biology, Biochemistry, Bioinformatics & Systems  Biology); Basic Medical Sciences (Molecular Medicine, Immunology, Biomedical  Engineering, Medical Technology)

 

Representative  Publications

1: co-first  author

 

1. Bai, P.,  Liu, Y., Xue, S., Charpin-El Hamri, G., Saxena, P., Ye, H., Xie,  M., and  Fussenegger, M. A fully human transgene switch to regulate therapeutic protein  production by cooling sensation. Nature Medicine  (2019) 25,  1266-1273.

2. Xie,  M. and  Fussenegger, M. Designing cell function: assembly of synthetic gene circuits for  cell-biology applications. Nature Reviews  Molecular Cell Biology (2018) 19,  507-525.

3. Liu, Y.,  Bai, P., Woischnig, A., Charpin-El Hamri, G., Ye, H., Folcher,  M., Xie,  M., Khanna, N.  and Fussenegger, M. Immunomimetic designer cells protect mice from  methicillin-resistant Staphylococcus aureus infection. Cell  (2018) 174,  1-12.

4. Bojar, D.,  Scheller, L., Charpin-El Hamri, G., Xie,  M. and  Fussenegger, M. Caffeine-inducible gene switches controlling experimental  diabetes. Nature  Communications (2018) 9:2318.

5. Wang,  H., Xie,  M., Charpin-El  Hamri, G., Ye, H. and Fussenegger, M. Treatment of chronic pain by designer  cells controlled by spearmint aromatherapy. Nature  Biomedical Engineering (2018) 2,  114–123.

6. Xie,  M., Aubel, D. and  Fussenegger, M. Closed-Loop Control Systems – the Quest for Precision Medicines  for Diabetes. Current Opinion  in Systems Biology (2017) 5,  32-40.

7. Shao, J.,  Xue, S., Yu, G., Yu, Y., Yang, X., Bai, Y., Zhu, S., Yang, L., Yin, J., Wang,  Y., Liao, S., Guo, S., Xie,  M., Fussenegger,  M. and Ye, H. Smartphone-controlled optogenetically engineered cells enable  semi-automatic glucose homeostasis in diabetic mice. Science  Translational Medicine (2017) 9,  eaal2298.

8. Xue, S.,  Yin, J., Shao, J., Yu, Y., Yang, L., Wang, Y., Xie,  M., Fussenegger,  M. and Ye, H. A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting  and Treating Hepatogenous Diabetes. Molecular  Therapy (2017) 25,  2.

9. Ye,  H.1Xie,  M.1, Xue, S.,  Charpin-El Hamri, G., Yin, J., Zulewski, H. and Fussenegger, M.  Self-adjusting  synthetic gene circuit for correcting insulin resistance. Nature  Biomedical Engineering (2017) 15.

10. Xie,  M., Ye, H., Wang,  H., Charpin-El Hamri, G., Lormeau, C., Saxena, P., Stelling, J. and Fussenegger,  M. β-cell-mimetic designer cells provide closed-loop glycemic  control. Science  (2016) 354,  1296-1301.

11. Xie,  M., Haellman, V.  and Fussenegger, M. Synthetic biology - application-oriented cell  engineering. Current Opinion  in Biotechnology (2016) 40,  139-148.

12. Bai, P.,  Ye, H., Xie,  M., Saxena, P.,  Zulewski, H., Charpin-El Hamri, G., Djonov, V. and Fussenegger, M. A synthetic  biology-based device prevents liver injury in mice. Journal of  Hepatology (2016) 65,  84-94.

13. Xie,  M. and  Fussenegger, M. Mammalian designer cells: Engineering principles and biomedical  applications. Biotechnology  Journal (2015) 10,  1005-1018. 

14. Wang, H.,  Ye, H., Xie,  M., Daoud  El-Baba, M. and Fussenegger, M. Cosmetics-triggered percutaneous remote control  of transgene expression in mice. Nucleic acids  research (2015) 43,  e91.

15. Xie,  M., Ye, H.,  Charpin El-Hamri, G. and Fussenegger, M. Antagonistic control of a dual-input  mammalian gene switch by food additives. Nucleic acids  research (2014) 42,  e116.

16. Folcher,  M.1Xie,  M.1, Spinnler, A.  and Fussenegger, M. Synthetic mammalian trigger-controlled bipartite  transcription factors. Nucleic acids  research (2013) 41,  e134.

17. Krawczyk, K., Xue, S., Buchmann, P., Charpin-El Hamri, G., Saxena, P., Hussherr, M.-D., Shao, J., Ye, H., Xie, M., and Fussenegger, M. Electrogenetic cellular insulin release for real-time glycemic control in type 1 diabetic mice. Science (2020) 368, 993–1001.

18. Meyer, C., Liu, J., Craciun, I., Wu, D., Wang, H., Xie, M., Fussenegger, M., and Palivan, C. Segregated Nanocompartments Containing Therapeutic Enzymes and Imaging Compounds Within DNA-Zipped Polymersome Clusters for Advanced Nanotheranostic Platform. Small (2020)1906492.